Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer

Lung Cancer

Volumn 66, Issue 2, 2009, Pages 176-183

  Gu, Tao ^a   Ohashi, Rina ^a   Cui, Ri ^a   Tajima, Ken ^a   Yoshioka, Masakata ^a   Iwakami, Shinichiro ^a   Sasaki, Shinichi ^a   Shinohara, Atsuko ^a,b   Matsukawa, Takehisa ^a   Kobayashi, Jun ^a   Inaba, Yutaka ^a,c   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Seisen University   (Japan)

^c JISSEN WOMEN'S UNIVERSITY   (Japan)

Author keywords

Chemo resistance; Cisplatin; Lung cancer; Osteopontin

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; MULTIDRUG RESISTANCE PROTEIN; OSTEOPONTIN; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STABLE TRANSFECTION;

ANTINEOPLASTIC AGENTS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; OSTEOPONTIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; TRANSFECTION;

EID: 70350302254     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.004     Document Type: Article

References (35)

1. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2 (2002) 277-288
2. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63 (2007) 12-31
3. Oldberg A., Franzen A., and Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83 (1986) 8819-8823
4. Butler W.T. Structural and functional domains of osteopontin. Ann N Y Acad Sci 760 (1995) 6-11
5. Gillespie M.T., Thomas R.J., Pu Z.Y., Zhou H., Martin T.J., and Findlay D.M. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 73 (1997) 812-815
6. Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79 (1998) 127-132
7. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287 (2002) 1671-1679
8. Zhang J., Takahashi K., Takahashi F., Shimizu K., Ohshita F., Kameda Y., et al. Differential osteopontin expression in lung cancer. Cancer Lett 171 (2001) 215-222
9. Donati V., Boldrini L., Dell'Omodarme M., Prati M.C., Faviana P., Camacci T., et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11 (2005) 6459-6465
10. Cui R., Takahashi F., Ohashi R., Gu T., Yoshioka M., Nishio K., et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57 (2007) 302-310
11. Lee J.L., Wang M.J., Sudhir P.R., Chen G.D., Chi C.W., and Chen J.Y. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44 V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67 (2007) 2089-2097
12. Graessmann M., Berg B., Fuchs B., Klein A., and Graessmann A. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 26 (2007) 2840-2850
13. Menendez J.A., Vellon L., Mehmi I., Teng P.K., Griggs D.W., and Lupu R. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 24 (2005) 761-779
14. Takahashi F., Akutagawa S., Fukumoto H., Tsukiyama S., Ohe Y., Takahashi K., et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 98 (2002) 707-712
15. Milacic R., Cemazar M., and Sersa G. Determination of platinum in tumour tissues after cisplatin therapy by electrothermal atomic absorption spectrometry. J Pharm Biomed Anal 16 (1997) 343-348
16. Heinegard D., Andersson G., and Reinholt F.P. Roles of osteopontin in bone remodeling. Ann N Y Acad Sci 760 (1995) 213-222
17. Brown L.F., Papadopoulos-Sergiou A., Berse B., Manseau E.J., Tognazzi K., Perruzzi C.A., et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 145 (1994) 610-623
18. Weber G.F., Ashkar S., Glimcher M.J., and Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271 (1996) 509-512
19. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5 (2004) 21-53
20. Ushijima R., Takayama K., Izumi M., Harada T., Horiuchi Y., Uchino J., et al. Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 27 (2007) 4351-4358
21. Ohashi R., Takahashi F., Cui R., Yoshioka M., Gu T., Sasaki S., et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett 252 (2007) 225-234
22. Khan S.A., Lopez-Chua C.A., Zhang J., Fisher L.W., Sorensen E.S., and Denhardt D.T. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85 (2002) 728-736
23. Fulda S., and Debatin K.M. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci 1028 (2004) 150-156
24. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
25. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
26. Sartorius U.A., and Krammer P.H. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97 (2002) 584-592
27. Kumar Biswas S., Huang J., Persaud S., and Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 3 (2004) 327-334
28. Han Z., Hong L., Han Y., Wu K., Han S., Shen H., et al. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 26 (2007) 261-268
29. Vaux D.L., Cory S., and Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335 (1988) 440-442
30. Tantivejkul K., Loberg R.D., Mawocha S.C., Day L.L., John L.S., Pienta B.A., et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 96 (2005) 641-652
31. Liu D.C., Zang C.B., Liu H.Y., Possinger K., Fan S.G., and Elstner E. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin 25 (2004) 1312-1319
32. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284 (1999) 156-159
33. Fernandes-Alnemri T., Litwack G., and Alnemri E.S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269 (1994) 30761-30764
34. Zohar R., Zhu B., Liu P., Sodek J., and McCulloch C.A. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway. Am J Physiol Heart Circ Physiol 287 (2004) H1730-H1739
35. Zohar R., Suzuki N., Suzuki K., Arora P., Glogauer M., McCulloch C.A., et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184 July (1) (2000) 118-130